<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539314</url>
  </required_header>
  <id_info>
    <org_study_id>274:7/2019</org_study_id>
    <nct_id>NCT04539314</nct_id>
  </id_info>
  <brief_title>Unilateral Transversus Abdominis Plane Block in Pediatrics</brief_title>
  <official_title>Dexmedetomidine as an Adjuvant to Bupivacaine in Unilateral Transversus Abdominis Plane Block in Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the present study was designed to compare the efficacy and safety of two different doses of&#xD;
      dexmedetomidine as an adjuvant to bupivacaine in unilateral TAP block in pediatric patients&#xD;
      undergoing lower abdominal surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After insertion of venous access, all children received premedication in the form of atropine&#xD;
      at a dose of 0.01-0.02 mg/kg. Perioperative monitoring included continuous ECG, pulse&#xD;
      oximetry and non-invasive arterial blood pressure. Baseline reading of heart rate, mean&#xD;
      arterial blood pressure was recorded after monitor attachment.&#xD;
&#xD;
      General anesthesia will be induced using propofol 1.5-2.5 mg/kg over 20-30 s as tolerated,&#xD;
      atracurium 0.5 mg/kg to facilitate endotracheal intubation. Anesthesia will be maintained&#xD;
      using isoflurane (1 MAC) and atracurium 0.1 mg/kg supplements will be given to maintain&#xD;
      muscle relaxation.&#xD;
&#xD;
      TAP block will be performed in All patients immediately after induction patients will be&#xD;
      allocated randomly into three equal groups, 30 patients in each as the following.&#xD;
&#xD;
      Group 1 (control group) TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)&#xD;
      Group 2 We will carry out TAP block using the same dose of bupivacaine in the control group&#xD;
      plus dexmedetomidine 0.5 μg / kg as an adjuvant Group (3) In this participants&#xD;
      dexmedetomidine in dose 1 μg / kg will be given as an adjuvant to the control dose of&#xD;
      bupivacaine in the TAP block TAP block procedure With the patient in the supine position, the&#xD;
      site of the ultrasound and needle entry was sterilized. The TAP block will be performed&#xD;
      laterally behind the midaxillary line between the iliac crest and the most inferior extent of&#xD;
      the ribs. The plane between the internal oblique and transversus abdominis muscle located&#xD;
      around the midaxillary line with the probe transverse to the abdomen. Anteriorly, the needle&#xD;
      passes to come perpendicular to the ultrasound beam and placed between transversus and&#xD;
      internal oblique posterior to the midaxillary line. Then, the local anesthetic will be&#xD;
      injected. (Al-Sadek et al.,2014).&#xD;
&#xD;
      The procedure will be performed immediately after induction of anesthesia by candidate&#xD;
      anesthesiologist who is not aware of group allocation.&#xD;
&#xD;
      After completion of surgical procedure anesthesia will be discontinued, muscle relaxant&#xD;
      reversed using atropine 0.02 mg/kg and 0.05 mg/kg of neostigmine, extubated, and transferred&#xD;
      to PACU.&#xD;
&#xD;
      Parameters will be assessed&#xD;
&#xD;
      • Quality of analgesia will be assessed immediately postoperatively and then at 2, 4, 8, 12&#xD;
      and 24 h postoperatively using FLACC scale (face,leg,activity,cry and consolability).&#xD;
&#xD;
      Time to the first analgesic requirement will be recorded from immediately postoperative to&#xD;
      the time of FLACC score &gt;6. Acetaminophen (perfalgan) 15 mg/kg IV will be given as rescue&#xD;
      analgesia for patients if FLACC score &gt;6 and total dose of acetaminophen will be recorded.&#xD;
&#xD;
      • Hemodynamic data including heart rate (HR) and mean arterial blood pressure (MAP).&#xD;
&#xD;
      Intraoperative any increase in heart rate and or mean arterial blood pressure by more than&#xD;
      20% of baseline values in response to surgical stimulus or thereafter throughout the whole&#xD;
      operation warranted administration of intravenous fentanyl (0.5 μg/kg).&#xD;
&#xD;
        -  postoperative complication including postoperative hypotension or bradycardia (decrease&#xD;
           in MAP or HR by more than 20% of baseline value), postoperative nausea and vomiting&#xD;
           (PONV)&#xD;
&#xD;
        -  length of hospital stays, and patients or parents' satisfaction assessed on a 5-point&#xD;
           scale (Al-Sadek et al.,2014) 1-completely dissatisfied, 2-dissatisfied, 3-not satisfied&#xD;
           nor dissatisfied, 4- satisfied 5-completely satisfied&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of analgesia</measure>
    <time_frame>24 hours after block</time_frame>
    <description>Quality of analgesia will be assessed by using FLACC scale (face,leg,activity,cry and consolability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>For 24 hours after surgery</time_frame>
    <description>postoperative complication including postoperative hypotension or bradycardia (decrease in MAP or HR by more than 20% of baseline value), postoperative nausea and vomiting (PONV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parents' satisfaction</measure>
    <time_frame>24 hours</time_frame>
    <description>parents' satisfaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Unilateral TAP Block in Pediatric Patients Undergoing Lower Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5 μg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 0.5 μg / kg as an adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1 μg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP block will be performed using (0.5 ml/ kg bupivacaine 0.25%) plus dexmedetomidine 1 μg / kg as an adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacain</intervention_name>
    <description>We will carry out the TAP block using 0.5 ml/ kg bupivacaine 0.25%</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine o.5 μg</intervention_name>
    <description>We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 0.5 μg / kg</description>
    <arm_group_label>Dexmedetomidine 0.5 μg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine 1 μg</intervention_name>
    <description>We will carry out the TAP block using using 0.5 ml/ kg bupivacaine 0.25% with dexmedetomidine 1 μg / kg</description>
    <arm_group_label>Dexmedetomidine 1 μg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA class I or II, aged from 1-7 years old undergoing any lower abdominal surgery that&#xD;
             requires skin incision in one side of midline of the anterior abdominal wall&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants refusing regional block and those having bleeding disorders, skin lesions&#xD;
             or wounds at the site of proposed needle insertion, evidence of peritonitis,&#xD;
             septicemia and hepatic disease or enlargement in addition to those who required&#xD;
             emergency procedures or operations that requires exploratory longitudinal midline&#xD;
             incision were excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minya University</name>
      <address>
        <city>Minya</city>
        <zip>61519</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haidy S Mansour, MD</last_name>
      <phone>0122182324</phone>
      <phone_ext>+2</phone_ext>
      <email>haidy_mourad@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minia University</investigator_affiliation>
    <investigator_full_name>haidy salah mansour</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

